Table 2.
Claudin 18.2 expression and correlation with clinicopathological characteristics of pancreatic ductal adenocarcinoma
| Clinicopathological parameter | Variable | Total valid, n (%) |
CLDN18.2 expression
|
P value | |
|
Positive, n (%)
|
Negative, n (%)
|
||||
| Age | < 63 | 49 (52.7) | 23 (46.9) | 26 (53.1) | 0.680 |
| ≥ 63 | 44 (47.3) | 23 (52.3) | 21 (47.7) | ||
| Sex | Female | 44 (47.3) | 24 (54.5) | 20 (45.5) | 0.409 |
| Male | 49 (52.7) | 22 (44.9) | 27 (55.1) | ||
| Localization | Head and neck | 52 (65.0) | 23 (44.2) | 29 (55.8) | 0.350 |
| Body and tail | 28 (35.0) | 16 (57.1) | 12 (42.9) | ||
| CA199 | High1 | 65 (81.3) | 33 (50.8) | 32 (49.2) | 0.570 |
| Normal2 | 15 (18.7) | 6 (40.0) | 9 (60.0) | ||
| T category | T1 | 14 (15.1) | 6 (42.9) | 8 (57.1) | 0.773 |
| T2 | 47 (50.5) | 24 (51.1) | 23 (48.9) | ||
| T3 | 26 (28.0) | 14 (53.8) | 12 (46.2) | ||
| T4 | 6 (6.4) | 2 (33.3) | 4 (66.7) | ||
| T1 + T2 | 61 (65.6) | 30 (49.2) | 31 (50.8) | 1.000 | |
| T3 + T4 | 32 (34.4) | 16 (50.0) | 16 (50.0) | ||
| T1 | 14 (15.1) | 6 (42.9) | 8 (57.2) | 0.773 | |
| T2 + T3 + T4 | 79 (84.9) | 40 (50.6) | 39 (49.4) | ||
| N category | N0 | 57 (61.3) | 23 (40.4) | 34 (59.6) | 0.019a |
| N1 | 27 (29.0) | 15 (55.6) | 12 (44.4) | ||
| N2 | 9 (9.7) | 8 (88.9) | 1 (11.1) | ||
| N0 | 57 (61.3) | 23 (40.4) | 34 (59.6) | 0.034a | |
| N1 + N2 | 36 (38.7) | 23 (63.9) | 13 (36.1) | ||
| M category | M0 | 79 (84.9) | 35 (44.3) | 44 (55.7) | 0.022a |
| M1 | 14 (15.1) | 11 (78.6) | 3 (21.4) | ||
| AJCC stage | I | 38 (40.9) | 16 (42.1) | 22 (57.9) | 0.058 |
| II | 28 (30.1) | 11 (39.3) | 17 (60.7) | ||
| III | 13 (14.0) | 8 (61.5) | 5 (38.5) | ||
| IV | 14 (15.0) | 11 (78.6) | 3 (21.4) | ||
| I | 38 (40.9) | 16 (42.1) | 22 (57.9) | 0.293 | |
| II + III + IV | 55 (59.1) | 30 (54.5) | 25 (45.5) | ||
| I + II | 66 (71) | 27 (40.9) | 39 (59.1) | 0.012a | |
| III + IV | 27 (29) | 19 (70.4) | 8 (29.6) | ||
| I + II + III | 79 (84.9) | 35 (44.3) | 44 (55.7) | 0.022a | |
| IV | 14 (15.1) | 11 (78.6) | 3 (21.4) | ||
| Local infiltration | Yes | 57 (71.3) | 29 (50.9) | 28 (49.1) | 0.625 |
| No | 23 (28.7) | 10 (43.5) | 13 (56.5) | ||
| Vascular invasion | Yes | 12 (15.0) | 7 (58.3) | 5 (41.7) | 0.542 |
| No | 68 (85.0) | 32 (47.1) | 36 (52.9) | ||
| Nerve invasion | Yes | 23 (28.7) | 17 (73.9) | 6 (26.1) | 0.006b |
| No | 57 (71.3) | 22 (38.6) | 35 (61.4) | ||
| Vessel carcinoma embolus | Yes | 27 (33.8) | 13 (48.1) | 14 (51.9) | 1.000 |
| No | 53 (66.2) | 26 (49.1) | 27 (50.9) | ||
| Grading | G1/G2 | 45 (48.4) | 20 (44.4) | 25 (55.6) | 0.409 |
| G3 | 48 (51.6) | 26 (54.2) | 22 (45.8) | ||
a
P < 0.05.
b
P < 0.01.
1
High indicates CA199 > 39 U/mL.
2
Normal indicates CA199 ≤ 39 U/mL.
AJCC: American Joint Committee on Cancer; CLDN18.2: Claudin 18.2.